TrialCancer2014

Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib.

Boe S Sorensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.